Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Drug Profile

Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Alternative Names: CASC-578; S024; S070; S081; S091; S158; S209

Latest Information Update: 09 Jun 2016

Price : $50

At a glance

  • Originator Sentinel Oncology
  • Developer Cascadian Therapeutics; Sentinel Oncology
  • Class Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; DNA repair inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
  • 19 Apr 2016 Preclinical data presented at the American Association for Cancer Research (AACR-2016)
  • 14 Mar 2016 Preclinical development is ongoing United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top